Although therapeutic mAbs against growth factor receptors EGFR and HER2 have shown promising results, their efficacy can be compromised due to the emergence of multiple resistance mechanisms attributable to the tumor's genetic and pathophysiological characteristics (detailed in section 3). Here, ERBB2 is linked to neoplasm.